论文部分内容阅读
Suberoylanilide hydroxamic acid (SAHA) is a well-known pan HDAC inhibitor and its clinical application (Vorinostat) has beendemonstrated to treat non-small cell lung cancer (NSCLS).Nevertheless,the impact of SAHA treatment on histone lysine acetylationand proteome in NSCLS cells still need further elucidate.In NSCLS A549 cells,by using stable isotope labeling for cell culture (SILAC)based quantitative proteomics,biochemistry assay and bioinformatic analysis,here we for the first time comprehensively identifiedand quantified histone lysine acetylation in A549 cells towards SAHA treatment.